Search Result

Results for "

corticotrophin-releasing factor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CRFR (4) Isotope-Labeled Compounds (1)
By Research Areas:	Cancer (2) Neurological Disease (2)

Inhibitors & Agonists

Isotope-Labeled Compounds

Targets Recommended: CRFR GnRH Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113603

Tildacerfont SPR001; LY2371712	CRFR	Cancer
Tildacerfont is a potent and orally active corticotrophin-releasing factor type 1 (CRF1) receptort antagonis. Tildacerfont effectively reduces adrenocorticotropic hormone (ACTH) and adrenal androgen levels. Tildacerfont has favourable safety profile. Tildacerfont can be used for researching congenital adrenal hyperplasia .

HY-124475

Antalarmin 2 Publications Verification	CRFR	Neurological Disease
Antalarmin is a selective nonpeptide corticotropin-releasing factor receptor 1 (CRHR1) antagonist with a K_i of 2.7 nM. Antalarmin can pass through the blood–brain barrier .

HY-113603S

Tildacerfont-d8 SPR001-d₈; LY2371712-d₈	Isotope-Labeled Compounds CRFR	Cancer
Tildacerfont-d₈ (SPR001-d₈) is a deuterium labeled Tildacerfont (HY-113603). Tildacerfont is a potent and orally active corticotrophin-releasing factor type 1 (CRF1) receptort antagonis. Tildacerfont effectively reduces adrenocorticotropic hormone (ACTH) and adrenal androgen levels. Tildacerfont has favourable safety profile. Tildacerfont can be used for researching congenital adrenal hyperplasia .

HY-124475R

Antalarmin (Standard)	CRFR	Neurological Disease
Antalarmin (Standard) is the analytical standard of Antalarmin. This product is intended for research and analytical applications. Antalarmin is a selective nonpeptide corticotropin-releasing factor receptor 1 (CRHR1) antagonist with a Ki of 2.7 nM. Antalarmin can pass through the blood–brain barrier .

Cat. No.	Product Name	Chemical Structure

HY-113603S

Tildacerfont-d8
Tildacerfont-d₈ (SPR001-d₈) is a deuterium labeled Tildacerfont (HY-113603). Tildacerfont is a potent and orally active corticotrophin-releasing factor type 1 (CRF1) receptort antagonis. Tildacerfont effectively reduces adrenocorticotropic hormone (ACTH) and adrenal androgen levels. Tildacerfont has favourable safety profile. Tildacerfont can be used for researching congenital adrenal hyperplasia .

Tildacerfont-d8

Tildacerfont-d₈ (SPR001-d₈) is a deuterium labeled Tildacerfont (HY-113603). Tildacerfont is a potent and orally active corticotrophin-releasing factor type 1 (CRF1) receptort antagonis. Tildacerfont effectively reduces adrenocorticotropic hormone (ACTH) and adrenal androgen levels. Tildacerfont has favourable safety profile. Tildacerfont can be used for researching congenital adrenal hyperplasia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.